Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue SUPPL. 1, 2005, Pages

  Ward, Penelope ^a   Small, Ian ^a   Smith, James ^b   Suter, Pia ^b   Dutkowski, Regina ^c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Neuraminidase inhibitors; Therapy; Treatment

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE DERIVATIVE; AMANTADINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; LIVER ENZYME; OSELTAMIVIR; PLACEBO; PRODRUG; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR; ACETAMIDE DERIVATIVE;

ABDOMINAL PAIN; AGE; AVIAN INFLUENZA; BRONCHITIS; CHEMOPROPHYLAXIS; CHILD CARE; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; DERMATITIS; DIARRHEA; DISEASE TRANSMISSION; DIZZINESS; DOSE CALCULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MARKETING; DRUG OVERDOSE; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; EAR DISEASE; ECZEMA; EPIDEMIC; EPISTAXIS; ERYTHEMA; ERYTHEMA MULTIFORME; EVIDENCE BASED MEDICINE; FACE EDEMA; FATIGUE; FETUS MALFORMATION; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HEADACHE; HEALTH CARE PLANNING; HEALTH HAZARD; HEPATITIS; HERPES SIMPLEX; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INFORMATION PROCESSING; INSOMNIA; LIVER DYSFUNCTION; LOW DRUG DOSE; NAUSEA; NONHUMAN; NOSE CONGESTION; OUTCOMES RESEARCH; PNEUMONIA; PREGNANCY; REVIEW; SHORT COURSE THERAPY; SKIN ALLERGY; SORE THROAT; SPECIES DIFFERENCE; STEVENS JOHNSON SYNDROME; URTICARIA; VERTIGO; VIRUS RESISTANCE; VIRUS STRAIN; VOMITING; CHEMISTRY; DRUG EFFECT; MORTALITY; ORTHOMYXOVIRUS; RISK ASSESSMENT; VIROLOGY;

ACETAMIDES; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; OSELTAMIVIR; RISK ASSESSMENT;

EID: 14744293108     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki018     Document Type: Review

References (95)

1. Lamb, R. A. & Krug, R. M. (2001). Orthomyxoviridae: the viruses and their replication. In Fields Virology, 4th edn (Knipe, D. M. & Howley, P. M. Eds), pp. 1487-531. Lippincott, Williams, and Wilkins, Philadelphia, PA, USA.
2. Wiley, D. C. & Skehel, J. J. (1987). The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annual Review of Biochemistry 56, 365-94.
3. Goto, H., Wells, K., Takada, A. et al. (2001). Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. Journal of Virology 75, 9297-301.
4. Palese, P., Tobita, K., Ueda, M. et al. (1974). Characterization of temperature-sensitive influenza virus mutants defective in neuraminidase. Virology 61, 397-410.
5. Schulman, J. L. & Palese, P. (1975). Susceptibility of different strains of influenza A virus to the inhibitory effects of 2-deoxy 2,3-dehydro-n-trifluoracetylneuraminic acid (FANA). Virology 63, 98-104.
6. Scholtissek, C., Quack, G., Klenk, H. D. et al. (1998). How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Research 37, 83-95.
7. Wainright, P. O., Perdue, M. L., Brugh, M. et al. (1991). Amantadine resistance among hemagglutinin subtype 5 strains of avian influenza virus. Avian Diseases 35, 31-9.
8. Hayden, F. G., Belshe, R. B., Clover, R. D. et al. (1989). Emergence and apparent transmission of rimantadine-resistant influenza A viruses in families. New England Journal of Medicine 321, 1696-702.
9. Treanor, J. J., Hayden, F. G., Vrooman, P. S. et al. (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Journal of the American Medical Association 283, 1016-24.
10. Nicholson, K. G., Aoki, F. Y., Osterhaus, A. D. M. E. et al. (2000). Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355, 1845-50.
11. Calfee, D. P., Peng, A. W., Cass, L. M. et al. (1999). Protective efficacy of intravenous zanamivir in experimental human influenza A virus infection. Antimicrobial Agents and Chemotherapy 43, 1616-20.
12. Hayden, F. G., Osterhaus, A. D., Treanor, J. U. J. et al. (1997). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GC167 Influenza Study Group. New England Journal of Medicine 337, 874-80.
13. Oxford, J. (2000). Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Reviews of Medical Virology 10, 119-33.
14. Potter, C. W. (2001). A history of influenza. Journal of Applied Microbiology 91, 572-9.
15. Taubenberger, J. K., Reid, A. H., Krafft, A. E. et al. (1997). Initial genetic characterization of the 1918 'Spanish' influenza virus. Science 275, 1793-6.
16. Nguyen-Van-Tam, J. & Hampton, A. W. (2003). The epidemiology and clinical impact of pandemic influenza. Vaccine 21, 1762-8.
17. http://www.who.int/csr/resources/publications/influenza/ WHO_CDS_CSR_RMD_2004_8/en/ (19 November 2004, date last accessed)
18. http://www.cdc.gov/flu/avian/index.htm (19 November 2004, date last accessed).
19. De Jong, J. C., Rimmelzwaan, G. F., Fouchier, R. A. et al. (2000). Influenza virus: a master of metamorphosis. Journal of Infection 40, 218-28.
20. Horimoto, T., Fukuda, N., Iwatsuki-Horimoto, K. et al. (2004). Antigenic differences between H5N1 viruses isolated from humans in 1997 and 2003. Journal of Veterinary Medical Science (Tokyo) 66, 303-5.
21. Enserink, M. (2004). Bird flu infected 1000, Dutch researchers say. Science 306, 590b.
22. Koopmans, M., Wilbrink, B., Conyn, M. et al. (2004). Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363, 587-93.
23. Dybing, J. K., Schultz-Cherry, S., Swayne, D. E. et al. (2000). Distinct pathogenesis of Hong Kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. Journal of Virology 74, 1443-50.
24. Kuiken, T., Rimmelzwaan, G. F., Van Amerongen, G. et al. (2003). Pathology of human influenza A (H5N1) virus infection in Cynomolgus Macaques (Macaca fascicularis). Veterinary Pathology 40, 304-10.
25. Zitzow, L. A., Rowe, T., Morken, T. et al. (2002). Pathogenesis of avian influenza A (H5N1) viruses in ferrets. Journal of Virology 76, 4420-9.
26. Matrosovich, M. N., Matrosovich, T. Y., Gray, T. et al. (2004). Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. Journal of Virology 78, 12665-7.
27. Kilbourne, E. D., Laver, W. G., Schulman, J. L. et al. (1968). Antiviral activity of antiserum specific for an influenza virus neuraminidase. Journal of Virology 1, 281-8.
28. Schulman, J. L., Khakpour, M. & Kilbourne, E. D. (1968). Protective effects of specific immunity to viral neuraminidase on influenza virus infection in mice. Journal of Virology 2, 778-86.
29. Murphy, B. R., Kasel, J. A. & Chanock, R. M. (1972). Association of serum anti-neuraminidase antibody with resistance to influenza in man. New England Journal of Medicine 286, 1329-32.
30. Couch, R. B., Kasel, J. A., Gerin, J. L. et al. (1974). Induction of partial immunity to influenza by a neuraminidase-specific vaccine. Journal of Infectious Diseases 129, 411-9.
31. Beutner, K. R., Chow, T., Rubi, E. et al. (1979). Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. Journal of Infectious Diseases 140, 844-50.
32. Clements, M. L., Betts, R. F., Tierney, E. L. et al. (1986). Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. Journal of Clinical Microbiology 24, 157-60.
33. Roberts, N. A., Wiltshire, H. R., Mendel, D. B. et al. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase. Poster # 135, ASM Biodefense Research Meeting, Baltimore, March 2003. http://www.asmbiodefense.org/tuepos.asp (15 January 2005, date last accessed).
34. Mendel, D. B., Webster, R. G., Roberts, N. A. (1999). Inhibition of avian influenza neuraminidases by GS4071 (Ro 64-0802) in vitro. Roche Research Report W-143039, 2 February 1999.
35. Potier, M., Mameli, L., Belisle, M. et al. (1979). Fluorometric assay of neuraminidase with a sodium (4-Methylumbelliferyl-α-d-N-Acetylneuraminate) substrate. Analytical Biochemistry 94, 287-96.
36. Li, K. S., Xu, K. M., Peiris, J. S. et al. (2003). Characterization of H9 subtype influenza viruses from the ducks of southern China: a candidate for the next influenza pandemic in humans? Journal of Virology 77, 6988-94.
37. Trampuz, A., Prabhu, R. M., Smith, T. F. et al. (2004). Avian influenza: a new pandemic threat? Mayo Clinic Proceedings 79, 523-30.
38. Webster, R. G. (1997). Predictions for future human influenza pandemics. Journal of Infectious Diseases 176, Suppl. 1 S14-S19.
39. McKimm-Breschkin, J., Trivedi, T., Hampson, A. et al. (2003). Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrobial Agents and Chemotherapy 47, 2264-72.
40. Meijer, A., van der Goot, J. A., Koch, G., et al. (2004). Oseltamivir reduces transmission, morbidity and mortality of highly pathogenic avian influenza in chickens. In Options for the Control of Influenza V, (Kawaoka, Y., Ed), pp. 455-8. International Congress Series 1263, Elsevier BV, Netherlands.
41. Balasingham, S., Manvell, R., Shell, W. et al. (2004). Antiviral activity of oseltamivir carboxylate (Tamiflu) against a potential human pandemic influenza A virus (chicken H5N1). In Program and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract 3839. American Society for Microbiology, Washington, DC, USA.
42. Zambon, M., Hayden, F. G. and the Global Neuraminidase Inhibitor Susceptibility Network. (2001). Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Research 49, 147-56.
43. Tumpey, T. M., Garcia-Sastre, A., Mikulasova, A. et al. (2002). Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proceedings of the National Academy of Sciences, USA 99, 13849-54.
44. Leneva, I. A., Roberts, N., Govorkova, E. A. et al. (2000). The neuraminidase inhibitor GS4104(oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Research 48, 101-15.
45. Govorkova, E. A., Leneva, I. A, Goloubeva, O. G. et al. (2001). Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrobial Agents and Chemotherapy 45, 2723-32.
46. Hien, T. T., Liem, N. T., Dung, N. T. et al. (2004). Avian influenza (H5N1) in 10 patients in Vietnam. New England Journal of Medicine 350, 1179-88.
47. Singh, S., Barghoorn, J., Bagdonas, A. et al. (2003). Clinical benefits with oseltamivir in treating influenza in adult populations. Clinical Drug Investigation 23, 561-9.
48. Kaiser, L., Wat, C., Mills, T. et al. (2003). Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine 163, 1667-72.
49. Whitley, R. J., Hayden, F. G., Reisinger, K. S. et al. (2001). Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal 20, 127-33.
50. Machado, C. M., Boas, L. S., Mendes, A. V. et al. (2004). Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplantation 34, 111-4.
51. Aoki, F. Y., Macleod, M. D., Paggiaro, P. et al. (2003). Early administration of oral oseltamivir increases the benefits of influenza treatment. Journal of Antimicrobial Chemotherapy 51 123-9.
52. Hayden, F. G., Belshe, R., Villanueva, C. et al. (2004). Management of influenza in households; a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. Journal of Infectious Diseases 189, 440-9.
53. Hayden, F. G., Atmar, R. L., Schilling, M. et al. (1999). Use of selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New England Journal of Medicine 341, 1336-43.
54. Peters, P. H., Jr, Gravenstein, S., Norwood, P. et al. (2001). Long-term use of oseltamivir in the prophylaxis of influenza in a vaccinated frail older population. Journal of the American Geriatric Society 49, 1025-31.
55. Welliver, R., Monto, A. S., Carewicz, O. et al. (2001). Effectiveness of oseltamivir in preventing influenza in household contacts. A randomized controlled trial. Journal of the American Medical Association 285, 748-54.
56. Bowles, S. K., Lee, W., Simor, A. E. et al. (2002). Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. Journal of the American Geriatric Society 50, 608-16.
57. Parker, R., Loewen, N. & Skowronski, O. (2001). Experience with oseltamivir in the control of a nursing home influenza B outbreak. Canadian Communicable Disease Report 27, 37-40.
58. Chik, K. W., Li, C. K., Chan, P. K. et al. (2004). Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Medical Journal 10, 103-6.
59. Shijubo, N., Yamada, G., Takahashi, M. et al. (2002). Experience with oseltamivir in the control of nursing home influenza A outbreak. Internal Medicine 41, 366-70.
60. Harris, J. W. (1919). Influenza occurring in pregnant women. Journal of the American Medical Association 72, 978-83.
61. Freeman, D. W. & Barno, A. (1959). Deaths from Asian influenza associated with pregnancy. American Journal of Obstetrics and Gynecology 78, 1172-5.
62. Greenberg, M., Jacobziner, H., Pakter, J. et al. (1958). Maternal mortality in the epidemic of Asian influenza. New York City, 1957. American Journal of Obstetrics and Gynecology 76, 897-902.
63. Hakoda, S. & Nakatoni, T. (2000). A pregnant woman with influenza A encephalopathy in whom influenza A/Hong Kong virus (H3) was isolated from cerebrospinal fluid. Archives of Internal Medicine 160, 1041-5.
64. Yawn, D. H., Pyeatte, J. C., Joseph, J. M. et al. (1971). Transplacental transfer of influenza virus. Journal of the American Medical Association 216, 1022-3.
65. Kort, B. A., Cefalo, R. C. & Baker, V. V. (1986). Fatal influenza A pneumonia in pregnancy. American Journal of Perinatology 3, 179-82.
66. Mullooly, J. P., Barker, W. H. & Nolan, T. F. (1986). Risk of acute respiratory disease among pregnant women during influenza A epidemics. Public Health Reports 101, 205-11.
67. Neuzil, K. M., Reed, G. W., Mitchel, E. F., Jr et al. (1999). Influenza-associated morbidity and mortality in young and middle-aged women. Journal of the American Medical Association 281, 901-7.
68. Irving, W. L., James, D. K., Stephenson, T. et al. (2000). Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. British Journal of Obstetrics and Gynaecology 107, 1282-9.
69. Glezen, W. P., Decker, M. & Perrotta, D. M. (1997). Influenza virus infections in infants. Pediatric Infectious Disease Journal 16, 1065-8.
70. Glezen, W. P., Decker, M. & Perrotta, D. M. (1987). Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. American Review of Respiratory Disease 136, 550-5.
71. Glezen, W. P., Greenberg, S. B., Atmar, R. L. et al. (2000). Impact of respiratory virus infections on persons with chronic underlying conditions. Journal of the American Medical Association 283, 499-505.
72. Neuzil, K. M., Zhu, Y., Griffin, M. R. et al. (2002). Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. Journal of Infectious Diseases 185 147-52.
73. Tai, C. Y., Escarpe, P. A., Sidwell, R. W. et al. (1998). Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS4071. Antimicrobial Agents and Chemotherapy 42, 3234-41.
74. McKimm-Breschkin, J. L. (2000). Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Research 47, 1-17.
75. Roche. (2004). Summary of Viral Resistance Data in the Treatment and Prophylaxis of Adults and Children for Tamiflu - Roche Research Report 1015254, Update, May 2004.
76. Roberts, N. A. (2001). Treatment of influenza with neuraminidase inhibitors; virological implications. Philosophical Transactions of the Royal Society of London B 356, 1895-7.
77. Kiso, M., Mitamura, K., Sakai-Tagawa, Y. et al. (2004). Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364, 759-65.
78. JV16284: Phase II clinical trial of oseltamivir phosphate for an influenza treatment in pediatric patients; Roche, data on file.
79. Carr, J., Ives, J., Kelly, L. et al. (2002). Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vitro. Antiviral Research 54, 79-88.
80. Herlocher, M. L., Carr, J., Ives, J. et al. (2002). Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Research 54, 99-111.
81. Ives, J. A., Carr, J. A., Mendel, D. B. et al. (2002). The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antiviral Research 55, 307-17.
82. Carr, J., Roberts, N. & Herlocher, L. (2002). Further study of the transmission in ferrets of influenza A/H1N1 virus carrying a H274Y neuraminidase mutation for Tamiflu®, oseltamivir phosphate. Roche Research Report 1008171.
83. Herlocher, M. L., Truscon, R., Elias, S. et al. (2004). Transmission studies in ferrets of influenza viruses resistant to the antiviral oseltamivir. Journal of Infectious Diseases 190, 1627-30.
84. Ferguson, N. M., Mallett, S., Jackson, H. et al. (2003). A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. Journal of Antimicrobial Chemotherapy 51, 977-90.
85. NISN. (2004). Statement on antiviral resistance in influenza viruses. Weekly Epidemiological Record 79, 306-8.
86. Moscona, A. (2004). Oseltamivir resistant influenza? Lancet 364, 733-4.
87. Dutkowski, R., Thakrar, B., Froehlich, E. et al. (2003). Safety and pharmacology of oseltamivir in clinical use. Drug Safety 26, 787-801.
88. Nordstrom, B. L., Oh, K., Sacks, S. T. et al. (2004). Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. Antiviral Therapy 9, 187-95.
89. Hayden, F. G. (2001). Perspectives on antiviral use during pandemic influenza. Philosophical Transactions of the Royal Society of London B 356, 1877-84.
90. Stilianakis, N. I., Perelson, A. S. & Hayden, F. G. (1998). Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. Journal of Infectious Diseases 177, 863-73.
91. Longini, I. M., Jr, Halloran, M. E., Nizam, A. et al. (2004). Containing pandemic influenza with antiviral agents. American Journal of Epidemiology 159, 623-33.
92. Van Genugten, M. L., Heijnen, M. L. & Jager, J. C. (2003). A surveillance system for the real-time reporting of influenza activity. Disease Management and Health Outcomes 12, 197-206.
93. Monto, A. S., Rotthoff, J., Teich, E. et al. (2004). Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clinical Infectious Diseases 39, 459-64.
94. http://www.eiss.org (119 November 2004, date last accessed).
95. Uphoff, H., Groniewicz, I., Soriano, M. et al. (2004). A surveillance system for the real-time reporting of influenza activity. Disease Management and Health Outcomes 12, 197-206.